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A corrigendum on
Inhibition of VEGFR2 Activation and Its Downstream Signaling to ERK1/2 and Calcium by
Thrombospondin-1 (TSP1): In silico Investigation
by Bazzazi, H., Isenberg, J. S., and Popel, A. S. (2017). Front. Physiol. 8:48. doi: 10.3389/fphys.2017.
00048
In the original article, there was a mistake in the legend for Figure 3 as published.
“TSP1 inhibition of VEGFR2 signaling with enhanced VEGFR2 degradation. Two nanometer TSP1
is added for 10 min followed by 40 min of 50 ng/ml VEGF...” The correct legend appears below.
The authors apologize for this error and state that this does not change the scientific conclusions of
the article in any way.
“TSP1 inhibition of VEGFR2 signaling with enhanced VEGFR2 degradation. 2 nM TSP1 is
added for 10 min followed by 40 min of 50 ng/ml VEGF...”
Incorrect Author Name
An author name was incorrectly spelled as Jeffery S. Isenberg. The correct spelling is Jeffrey
S. Isenberg. The authors apologize for this error and state that this does not change the scientific
conclusions of the article in any way.
Text Correction
In the original article, there was an error on the Introduction section page 2, paragraph 3:
“...we set out here to interrogate potential mechanisms for the inhibition of VEGF/VEGFR2
signaling to ERK1/2 and calcium by TSP1/CD4 interaction utilizing a detailed rule-based model of
VEGF signaling to ERK1/2 and calcium...”
A correction has been made to Introduction, paragraph 3:
“...we set out here to interrogate potential mechanisms for the inhibition of VEGF/VEGFR2
signaling to ERK1/2 and calcium by TSP1/CD47 interaction utilizing a detailed rule-based model
of VEGF signaling to ERK1/2 and calcium...”
The authors apologize for this error and state that this does not change the scientific conclusions
of the article in any way.
In the original article, there was an error on the Conflict of Interest Statement:
“JI serves as chair of the scientific advisory boards of Radiation Control Technologies, Inc.
(Jersey City, NJ) and has equity interest in the same and in Tioma Therapeutics (St. Louis, MO).”
A correction has been made to Conflict of Interest Statement:
Bazzazi et al. TSP1 Inhibition of VEGFR2 Activation
“JI serves as chair of the scientific advisory board of Radiation
Control Technologies, Inc. (Jersey City, NJ) and has equity
interest in the same and in Tioma Therapeutics (St. Louis, MO).”
The authors apologize for this error and state that this does
not change the scientific conclusions of the article in any way.
Conflict of Interest Statement: JI serves as chair of the scientific advisory board
of Radiation Control Technologies, Inc. (Jersey City, NJ) and has equity interest in
the same and in Tioma Therapeutics (St. Louis, MO).
The other authors declare that the research was conducted in the absence of any
commercial or financial relationships that could be construed as a potential conflict
of interest.
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